Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

STE Steris SEC Filings & Insider Trading Activity 2026

company
CIK 175789898 filings
S&P 500

STE at a glance

Steris (STE, SEC CIK 1757898) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Steris (STE) shares worth $9.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Madsen Julia on November 13, 2026 of 2,046 shares at $260.00 per share.
  • In the last 90 days, STE insiders reported 0 open-market purchases ($0) and 4 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$5.9B
+8.7% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$3.3M
13F holders
38 funds
$9.0B · −3 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q2 revenue $1,588.6M, up 8.8% YoY from $1,460.3M
  • Gross margin 44.7% vs 44.2% YoY; operating income $294.3M vs $265.8M
  • Best segment Life Sciences: revenue $170.6M, up 17.7%; margin 44.4% vs 41.3%
  • Healthcare weakest margin trend: 24.0% vs 25.1%, despite revenue growth of 8.6% to $1,122.4M
  • Six-month operating cash flow $656.1M vs $707.8M; free cash flow $492.5M vs $527.7M, with $200.0M share repurchases

Risk Factors

  • New transaction risk: Xodus Medical Acquisition could fail to close, with termination permitted after July 12, 2027
  • Regulatory risk: Hart-Scott-Rodino approval and other antitrust clearances could require divestitures or remedies
  • Operational risk: Acquisition uncertainty could cause employee departures and customer, supplier, or partner disruptions
  • Financial risk: Approximately $2.0 billion additional debt expected, versus $1.9 billion outstanding at September 30, 2026
  • Financing risk: Bridge facility may carry higher costs and shorter maturities if permanent financing terms prove unacceptable

AI summary of the STE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 8.01: Other Events

  • $1.5B senior-note offering, split between $750M due 2033 and $750M due 2036
  • Fixed interest rates of 5.650% and 5.875%, respectively, increasing recurring interest expense
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • STERIS announced fiscal second-quarter 2026 results for the quarter ended September 30, 2026
  • Detailed financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Fiscal Q2 revenue $1.6B, up 9%, with 8.1% constant-currency organic growth, indicating broad underlying demand
  • Adjusted diluted EPS $2.94, up from $2.47, while GAAP EPS reached $2.19 from $1.94
Filed Nov 4, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • New $1.6B revolving facility replaces existing agreement, with maturity extended to November 4, 2031
  • Revolver supports liquidity, letters of credit and swingline borrowings, with potential $800M commitment expansion

Item 1.02: Termination of a Material Definitive Agreement

  • Existing Revolving Credit Agreement termination disclosed through Item 1.01 cross-reference
  • Investors should review Item 1.01 for replacement financing terms and potential liquidity implications

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
  • Investors should review Item 1.01 for the obligation’s amount, terms, maturity and business purpose

AI summaries of STE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for STE

Don't miss the next STE filing

  • Alerts as it files. A push when STE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut STE, by share count.
  • Ask anything. An AI agent that reads every STE filing and answers with sources.

STE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Madsen JuliaSellNov 13, 2026$260.00
Burton Karen LMNov 11, 2026-
Burton Karen LSellNov 11, 2026$255.62
Burton Karen LMNov 11, 2026$147.05
Sohi MohsenSellNov 10, 2026$252.87
Sohi MohsenMNov 10, 2026$114.74
Sohi MohsenSellNov 10, 2026$253.90
Sohi MohsenMNov 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$5.5B$5.9B
Gross Profit-$2.4B$2.6B
Operating Income-$866.6M$1.1B
Net Income-$614.6M$782.3M
Gross Margin-44.0%44.2%
Op. Margin-15.9%18.6%
Net Margin-11.3%13.2%
Balance Sheet
Total Assets$11.1B$10.1B$10.7B
Equity$6.3B$6.6B$7.2B
ROE-9.3%10.9%
Per Share
EPS-$6.20$7.93
Cash Flow
Operating CF-$1.1B$1.3B
CapEx-$370.1M$369.0M

Source: XBRL data in Steris (STE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate STE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
STE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$9.05B
Q2 202641$9.09B
Q1 202637$9.54B
Q4 202535$10.48B
Q3 202537$10.39B
Q2 202534$9.63B
Q1 202533$6.85B
Q4 202430$4.98B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 285 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

STE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 12, 2026--
8-KNov 12, 2026Analysis-
4Nov 12, 2026--
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
8-KNov 4, 2026Analysis-
8-KOct 13, 2026Analysis-
4Oct 5, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
8-KAug 6, 2026Analysis-
8-KAug 5, 2026Analysis-
4Jul 2, 2026--
4Jun 16, 2026--
4Jun 8, 2026-
4Jun 8, 2026-

Related Health Care companies

All Health Care →

STE SEC filings: frequently asked questions

Are STE insiders buying or selling?

In the last 90 days, Steris (STE) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $3.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold STE stock?

As of September 30, 2026, the largest Steris (STE) holders among the 13F filers tracked by SignalX were BlackRock ($2.1 billion), Vanguard Capital Management LLC ($1.3 billion), State Street Corp ($1.1 billion), Vanguard Portfolio Management LLC ($1.0 billion), Morgan Stanley ($765.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was STE's revenue in fiscal year 2026?

For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93. The figures come from the XBRL data in the 10-K.

What did STE report in its latest 8-K?

Steris (STE) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). $1.5B senior-note offering, split between $750M due 2033 and $750M due 2036.

What are the latest STE SEC filings?

Steris (STE) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 17, 2026.

What is STE's SEC CIK number?

Steris (STE)'s SEC Central Index Key (CIK) is 1757898. EDGAR lists every STE filing under that number.

Ask anything about STE

The research agent reads STE's filings, financials, insider trades and 13F holders, then answers with sources.